LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive
inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and …

LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …

Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …

7522 Background: When EGFR compound mutants (exon 19 deletions or L858R
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …